Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | Ft27.17 |
52 Week High | Ft29.58 |
52 Week Low | Ft21.47 |
Beta | 0.37 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | 69.31% |
Change since IPO | -84.86% |
Recent News & Updates
Recent updates
Shareholder Returns
RGED.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -2.6% | 0.7% |
1Y | n/a | 20.9% | 32.3% |
Return vs Industry: Insufficient data to determine how RGED.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RGED.F performed against the US Market.
Price Volatility
RGED.F volatility | |
---|---|
RGED.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RGED.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RGED.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1901 | 11,603 | Gabor Orban | www.gedeonrichter.com/hu-hu |
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. It operates through two segments, Pharmaceuticals, and Wholesale and Retail.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Fundamentals Summary
RGED.F fundamental statistics | |
---|---|
Market cap | US$5.62b |
Earnings (TTM) | US$644.47m |
Revenue (TTM) | US$2.28b |
8.7x
P/E Ratio2.5x
P/S RatioIs RGED.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RGED.F income statement (TTM) | |
---|---|
Revenue | Ft811.42b |
Cost of Revenue | Ft260.03b |
Gross Profit | Ft551.39b |
Other Expenses | Ft322.26b |
Earnings | Ft229.13b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
Earnings per share (EPS) | 1.26k |
Gross Margin | 67.95% |
Net Profit Margin | 28.24% |
Debt/Equity Ratio | 9.4% |
How did RGED.F perform over the long term?
See historical performance and comparison